See more : Intelligent Medicine Acquisition Corp. (IQMD) Income Statement Analysis – Financial Results
Complete financial analysis of AVITA Medical, Inc. (RCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVITA Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- UCAL Limited (UCAL.BO) Income Statement Analysis – Financial Results
- Sylph Technologies Limited (SYLPH.BO) Income Statement Analysis – Financial Results
- Tempus Resources Limited (TMR.AX) Income Statement Analysis – Financial Results
- JDE Peet’s N.V. (JDEP.AS) Income Statement Analysis – Financial Results
- Unidata S.p.A. (UD.MI) Income Statement Analysis – Financial Results
AVITA Medical, Inc. (RCEL)
About AVITA Medical, Inc.
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
| Metric | 2022 | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.56M | 14.26M | 20.67M | 1.26M | 1.18M | 1.00M | 985.65K | 2.68M | 2.81M | 3.35M | 3.34M | 2.30M | 2.37M | 1.20M | 790.99K | 883.39K | 389.08K | 194.32K | 0.00 | 0.00 | 0.00 | 582.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.87M | 2.97M | 4.31M | 737.70K | 505.64K | 401.57K | 289.20K | 670.89K | 676.50K | 952.85K | 972.78K | 669.45K | 824.23K | 492.31K | 1.13M | 1.06M | 940.26K | 98.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 41.69M | 11.29M | 16.36M | 517.47K | 675.00K | 600.44K | 696.45K | 2.01M | 2.14M | 2.40M | 2.36M | 1.63M | 1.54M | 711.35K | -337.70K | -176.85K | -551.18K | 95.34K | 0.00 | 0.00 | 0.00 | 582.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 82.45% | 79.16% | 79.16% | 41.23% | 57.17% | 59.92% | 70.66% | 75.00% | 75.97% | 71.58% | 70.84% | 70.85% | 65.18% | 59.10% | -42.69% | -20.02% | -141.66% | 49.06% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.35M | 8.46M | 13.28M | 8.45M | 6.27M | 3.46M | 3.77M | 2.15M | 2.60M | 969.11K | 255.54K | 164.79K | 181.85K | 163.83K | 620.67K | 1.33M | 425.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.27M | 34.62M | 46.77M | 12.70M | 0.00 | 6.51M | 2.45M | 4.27M | 5.45M | 5.34M | 5.42M | 3.40M | 3.87M | 3.98M | 5.36M | 5.64M | 2.21M | 725.90K | 480.40K | 569.49K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Selling & Marketing | 32.19M | 14.81M | 22.76M | 6.59M | 5.20M | 3.46M | 3.21M | 2.63M | 3.39M | 2.93M | 2.15M | 1.15M | 1.37M | 1.39M | 1.92M | 1.90M | 838.56K | 122.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.46M | 49.43M | 70.61M | 21.21M | 13.90M | 10.93M | 5.68M | 7.09M | 8.92M | 8.44M | 7.57M | 4.55M | 5.24M | 5.37M | 7.28M | 7.54M | 3.05M | 848.25K | 480.40K | 569.49K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Other Expenses | 0.00 | 686.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 852.27K | 886.45K | 41.73K | 5.88K | 4.27M | 85.29K | 240.35K | -1.28M | -24.61K | -2.08M | 28.27K | -956.00K | -1.56M | 1.52M | 910.39K | 40.34K | 16.93K |
| Operating Expenses | 80.78M | 53.97M | 77.21M | 19.15M | 13.35M | 11.95M | 9.26M | 8.83M | 10.77M | 10.66M | 7.89M | 5.23M | 5.91M | 5.75M | 8.75M | 9.62M | 4.87M | 169.38K | 670.01K | 76.87K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Cost & Expenses | 89.65M | 56.94M | 81.51M | 19.88M | 13.85M | 12.36M | 9.55M | 9.50M | 11.45M | 11.61M | 8.86M | 5.90M | 6.74M | 6.25M | 9.88M | 10.68M | 5.81M | 268.36K | 670.01K | 76.87K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Interest Income | 23.50K | 0.00 | 47.82K | 28.37K | 110.96K | 110.34K | 45.42K | 160.33K | 412.26K | 497.99K | 124.99K | 124.70K | 270.11K | 668.21K | 543.41K | 520.50K | 201.65K | 145.15K | 126.13K | 195.94K | 6.81K | 609.80 | 4.20K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.90K | 37.65K | 78.50K | 53.20K | 8.55M | 4.86K | 9.95K | 2.26K | 3.57 | 4.97M | 576.36K | 2.07M | 2.19M | 258.33K | 1.16M | 775.70 | -191.00K |
| Depreciation & Amortization | 1.46M | 465.00K | 0.00 | 105.45K | 139.70K | 83.72K | 62.62K | 63.71K | 121.92K | 569.23K | 650.88K | 517.57K | 491.49K | 221.96K | 852.62K | 745.94K | 702.81K | 111.83K | 189.60K | 76.87K | 595.35K | -923.38K | -2.19M | 578.99K | -1.16M | -1.96M | 49.44K |
| EBITDA | -39.57M | -41.53M | -61.17M | -18.55M | -12.53M | -11.27M | -8.68M | -6.76M | -8.51M | -5.62M | -3.89M | -2.08M | -3.57M | -4.15M | -3.69M | -8.45M | -4.27M | -1.39M | -390.45K | 575.84K | 359.65K | 582.97K | -2.29M | 440.17K | -1.29M | -2.23M | -158.49K |
| EBITDA Ratio | -78.26% | -291.16% | -295.97% | -1,478.04% | -1,061.34% | -1,124.79% | -880.69% | -251.79% | -302.36% | -167.75% | -116.76% | -90.46% | -150.78% | -344.42% | -466.58% | -956.13% | -1,097.89% | -717.25% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -40.40M | -42.68M | -61.84M | -18.70M | -12.67M | -11.35M | -8.74M | -6.82M | -8.63M | -6.19M | -4.38M | -2.59M | -4.06M | -4.37M | -4.54M | -9.19M | -4.97M | -1.62M | -1.29M | 498.37K | -235.70K | 1.51M | -97.16K | -138.81K | -126.55K | -278.48K | -207.93K |
| Operating Income Ratio | -79.91% | -299.23% | -299.23% | -1,489.88% | -1,073.17% | -1,133.14% | -887.04% | -254.16% | -306.69% | -184.73% | -131.31% | -113.00% | -171.55% | -362.86% | -574.37% | -1,040.57% | -1,278.53% | -832.34% | 0.00% | 0.00% | 0.00% | 258.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.29M | 686.00K | 946.20K | 43.24K | 110.96K | 110.34K | 222.97K | 160.33K | 412.26K | -1.57M | 3.23M | -1.82M | 41.73K | -7.58M | -4.55M | 85.29K | 240.35K | -1.58M | -735.53K | -1.16M | -567.08K | -956.00K | -1.56M | 1.52M | 911.13K | 99.29K | 158.49K |
| Income Before Tax | -39.12M | -42.03M | -60.90M | -18.66M | -12.56M | -11.24M | -8.52M | -6.66M | -8.22M | -7.76M | -2.18M | -5.34M | -4.14M | -12.00M | -13.09M | -9.20M | -4.98M | -1.51M | -1.29M | -1.63M | -812.06K | -563.08K | -2.29M | 184.42K | -1.29M | -2.18M | -16.93K |
| Income Before Tax Ratio | -77.36% | -294.65% | -294.65% | -1,486.44% | -1,063.77% | -1,122.13% | -864.42% | -248.18% | -292.04% | -231.47% | -65.24% | -232.33% | -174.86% | -997.23% | -1,655.44% | -1,041.12% | -1,281.08% | -775.96% | 0.00% | 0.00% | 0.00% | -96.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 52.88K | 4.00K | 5.80K | 1.45M | 1.05M | 971.88K | 653.67K | 1.51M | 128.05K | 87.76K | -90.09K | -330.41K | 78.50K | -342.23K | -316.55K | -311.92K | -7.13M | -2.69M | -2.53M | -2.94M | 576.36K | -923.38K | 2.19M | -581.57K | 1.16M | -238.92K | 208.61K |
| Net Income | -39.17M | -42.03M | -60.90M | -17.21M | -11.51M | -10.27M | -7.87M | -5.15M | -8.09M | -7.59M | -2.09M | -5.01M | -4.14M | -11.66M | -12.78M | -8.89M | -4.98M | -1.54M | -1.12M | -1.54M | -812.06K | -562.85K | -2.29M | 184.42K | -1.29M | -1.94M | -225.54K |
| Net Income Ratio | -77.47% | -294.68% | -294.68% | -1,370.83% | -974.99% | -1,025.14% | -798.10% | -191.84% | -287.49% | -226.42% | -62.54% | -217.95% | -174.86% | -968.80% | -1,615.42% | -1,005.81% | -1,281.08% | -794.76% | 0.00% | 0.00% | 0.00% | -96.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.57 | -2.07 | -3.00 | -1.84 | -1.72 | -2.06 | -2.23 | -1.58 | -2.69 | -3.19 | -1.53 | -3.93 | -3.75 | -16.51 | -3.24 | -3.43 | -3.14 | -1.92 | -0.56 | -0.80 | -1.32 | -2.25 | -48.58 | -0.74 | -27.28 | -42.11 | -5.06 |
| EPS Diluted | -1.57 | -2.07 | -3.00 | -1.85 | -1.72 | -2.06 | -2.23 | -1.58 | -2.69 | -3.19 | -1.53 | -3.93 | -3.75 | -16.51 | -3.24 | -3.43 | -3.14 | -1.92 | -0.56 | -0.80 | -1.32 | -2.25 | -48.58 | -0.74 | -27.28 | -42.11 | -5.06 |
| Weighted Avg Shares Out | 25.00M | 20.29M | 20.29M | 9.30M | 6.69M | 4.99M | 3.53M | 3.25M | 3.01M | 2.38M | 1.36M | 1.27M | 1.10M | 706.45K | 3.94M | 2.59M | 1.59M | 806.03K | 2.00M | 1.93M | 614.53K | 249.70K | 47.13K | 47.13K | 47.13K | 46.02K | 44.55K |
| Weighted Avg Shares Out (Dil) | 25.00M | 20.29M | 20.29M | 9.33M | 6.70M | 4.99M | 3.53M | 3.25M | 3.01M | 2.38M | 1.36M | 1.27M | 1.10M | 706.45K | 3.94M | 2.59M | 1.59M | 806.03K | 2.00M | 1.93M | 614.53K | 249.70K | 47.13K | 47.13K | 47.13K | 46.02K | 44.55K |
AVITA Medical Inks Supply Pact With Premier For RECELL System
AVITA Medical Inc (NASDAQ: RCEL) has been awarded a group purchasing agreement with Premier Inc (NASDAQ: PINC) The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the RECELL System for.
AVITA Medical Inc. (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript
AVITA Medical Inc. (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript
AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,...
AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,...
AVITA Medical Is Interesting, But Not Just Yet
The company is impacted by staffing issues and the pandemic which hamper growth at the moment, but the shares are already at a 52-week low.
AVITA Medical to Present at Upcoming Investor Conferences
VALENCIA, Calif., and MELBOURNE, Australia, Nov. 16, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,...
AVITA Medical, Inc.'s (RCEL) CEO Mike Perry on Q1 2022 Results - Earnings Call Transcript
AVITA Medical, Inc.'s (RCEL) CEO Mike Perry on Q1 2022 Results - Earnings Call Transcript
AVITA Medical, Inc. (RCEL) Soars 8%: Is Further Upside Left in the Stock?
AVITA Medical, Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AVITA Medical to Announce Fiscal First Quarter 2022 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,...
AVITA Medical to Present at the 2021 Cantor Virtual Global Healthcare Conference
VALENCIA, Calif., and MELBOURNE, Australia, Sept. 13, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,...
Source: https://incomestatements.info
Category: Stock Reports